Published in Vaccine Weekly, June 10th, 1996
Infusion of donor leukocytes has been shown to have a graft-vs-leukemia (GVL) effect after bone marrow transplantation. It has also been shown to be an effective treatment for EBV-associated posttransplant lymphoproliferative disease. It has been assumed that the beneficial effects of these donor grafts are mediated by tumor- or virus-specific cytotoxic T lymphocytes (CTLs) that are contained within the bulk T-cell population.
In spite of the ability of these unmanipulated lymphocytes to mediated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly